Answers are grounded in this paper and cite their sources.
Experimental findings demonstrate that Ru(bpy)₂Nic₂ triggers contractions in tracheal smooth muscle, indicating a role in nAChR activation.
Background. Ru(bpy)₂Nic₂, a bipyridine ruthenium complex, is a light-sensitive compound capable of releasing nicotine upon irradiation with visible light (420–470 nm). Given its high quantum yield (φs = 0.23), it offers precise control over nicotine release, making it a valuable tool for investigating nicotinic acetylcholine receptor (nAChR) activation in biomedical research. Methods. High-performance liquid chromatography (HPLC) and tensometric analysis of rat tracheal smooth muscle contractions were used in this study. Results. Experimental findings demonstrated that Ru(bpy)₂Nic₂ induces a phasic-tonic contraction pattern in rat tracheal smooth muscle. The phasic phase is initiated by nicotine, while photolysis by-products activate P2X and P2Y purinergic receptors and stimulate prostaglandin release from the tracheal epithelium, thereby contributing to the sustained tonic component of contraction. Conclusions. Overall, Ru(bpy)₂Nic₂ provides an efficient and controllable nicotine source for biomedical research, with high photolysis efficiency and the ability to generate biologically relevant nicotine concentrations using accessible light sources.
No takes yet. Share an insight, caveat, or question.
Kravchuk et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: